Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. MU
5. META
6. SPY
7. ACN
8. BLZE
9. IBM
10. NKE

Go back to Trevena Stock Trading Halted; FDA Advisory Committee to Review Oliceridine for the Treatment of Moderate to Severe Acute Pain

Trevena (TRVN) Confirms FDA Panel Voted 8 Against and 7 in Favor of Approval of Oliceridine

October 11, 2018 5:05 PM EDT

Trevena, Inc. (NASDAQ: TRVN), today announced the outcome of the meeting of the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) to review and discuss oliceridine. At the meeting, the Advisory Committee voted 8 against, and 7 in favor of, the approval of oliceridine for the management of moderate to severe acute pain in adult... More